---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-039634"
form_type: "8-K/A"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:28:48.372326+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa reports FY2023 results: $88.5M cash, R&D spend up; two Phase 2 trials fully enrolled

## Summary
- Ended FY2023 with $88.5M cash and equivalents, no debt.
- Total operating expenses were $31.4M, up from $27.7M in FY2022, driven by higher R&D and G&A.
- Two Phase 2 trials fully enrolled (Karisma-Endoxifen and I-SPY2); top-line data awaited H2 2024.
- Recorded $3.0M impairment charge on investment in DCT; interest income rose to $4.3M from $0.9M.
- Data from EVANGELINE Phase 2 study to be presented at AACR Annual Meeting on April 9, 2024.

## SEC filing metadata
- accession: 0000950170-24-039634
- form_type: 8-K/A
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024039634/0000950170-24-039634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024039634/atos-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-039634
- JSON: https://secwatch.observer/filing/0000950170-24-039634.json
- Plain text: https://secwatch.observer/filing/0000950170-24-039634.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000095017024039634/0000950170-24-039634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.